ClinicalTrials.gg
RecruitingNCT07080385CALIBRATE-PEDSUpdated Apr 22, 2026

Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

A Phase 2/3 interventional study of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1), sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company. Recruiting at 6 sites in 2 countries. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company (part of BridgeBio) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
0 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies in Hypocalcemia with a site in United States — 2 open to participants now, 5 under way, 2 of them phase 3. Hypocalcemia · United States.

Planned enrollment
16th of 25
28 · median 36
Started
2026
the only one that year
Phase 2/3
Only one
of the 30
Registered
30th of 30
by date
Lead sponsor
3 of 30
Calcilytix Therapeutics, Inc., a BridgeBio company

Among the 30 studies in Hypocalcemia with a site in United States, this one is the 16th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 2/3, and was the 30th registered.

Hypocalcemia

98 studies on the registry are indexed under Hypocalcemia; 16 are open to participants now.

Browse Hypocalcemia studies →

Open to participants now

2 of the 30 studies in Hypocalcemia with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Hypocalcemia studies recruiting now, 8 (73%) set no upper age limit and 2 (18%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 0 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Hypocalcemia with a site in United States, or all of them as a file.
02

Study summary

The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1.

03

Conditions studied

  • Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Browse trials for

Keywords

  • Autosomal dominant hypocalcemia type 1
  • ADH1
  • Encaleret
04

Who can participate

Ages eligible
0 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Provide written (if legally permitted), or have written informed consent from a parent/legal guardian and provide assent (where required and as appropriate per local requirements)
  • Have a documented pathogenic or likely pathogenic activating variant, or variant of uncertain significance of the calcium-sensing receptor (CASR), associated with biochemical findings of hypoparathyroidism at screening or a documented history of hypoparathyroidism as manifested by hypocalcemia and intact parathyroid hormone (PTH) \<40 picogram per milliliter (pg/mL) (4.2 picomoles per liter [pmol/L])
  • Have at least 1 symptom or sign of hypoparathyroidism at screening or a documented history of symptoms or signs of hypoparathyroidism
  • Be on ADH1 treatment for at least 6 months before screening for cohorts 1 to 3, or for at least 3 months before screening for cohort 4

Key Exclusion Criteria:

  • History of thyroid or parathyroid surgery
  • History of renal transplantation
  • History of cancer (except thyroid cancer, basal cell skin cancer, or squamous cell skin cancer), skeletal , bone , irradiation (radiotherapy) to the skeleton, chemotherapy with alkylating agents, Paget disease, fibrous dysplasia, chronic osteomyelitis, bone infarcts, benign bone tumors with curettage and bone grafts, retinoblastoma, or Li-Fraumeni syndrome within 5 years before screening
  • Received any medicinal product within 30 days or 5 half-lives before Day 1, whichever is longer, or is in follow-up for another interventional clinical study during screening
  • Treatment with a strong P-glycoprotein (P-gp) inhibitor within 300 days before screening for amiodarone or within 30 days before screening for any other strong P-gp inhibitor
  • Treatment with cardiac glycosides, or is being breastfed while the participant's nursing mother is treated with cardiac glycosides, within 30 days before screening
  • Presence or history of any disease or condition (eg, drug or alcohol dependence) that would affect the participant's safety, treatment compliance, or ability to complete the study, in the opinion of the investigator

Other protocol defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Encaleret

    Participants will receive encaleret dosing in Period 1 (6 days), Period 2 (20 weeks) and Period 3 (4 weeks). Following completion of Period 3, participants will have the option to enter a long-term extension (LTE) to continue encaleret for an additional approximately 24 months or until the sponsor decides to end the study, whichever occurs first.

    Drug: Encaleret

Interventions

  • Oral tablets, age-appropriate pediatric formulation (currently under development).

06

What researchers measure

Primary outcomes

  1. Period 1: Maximum Plasma Concentration (Cmax) of Encaleret and Metabolites M1, and M3

    Time frame: 5 days

  2. Period 1: Area Under the Plasma Concentration-time Curve (AUC) of Encaleret and Metabolites M1, and M3

    Time frame: 5 days

  3. Period 3: Number of Participants with Albumin-corrected Blood Calcium (cCa) and Urinary Calcium (UCa) Excretion Response

    Time frame: Week 25

Secondary outcomes

  1. Period 1: Change from Baseline in Blood cCa

    Time frame: Baseline up to Day 5

  2. Period 1: Change from Baseline in Blood Intact Parathyroid Hormone (iPTH) Concentration

    Time frame: Baseline up to Day 5

  3. Period 1: Change from Baseline in Blood Phosphate Concentration

    Time frame: Baseline up to Day 5

  4. Period 1: Change from Baseline in Blood 1,25-(OH)2 Vitamin D Concentration

    Time frame: Baseline up to Day 5

  5. Period 1: Change from Baseline in Blood Magnesium Concentration

    Time frame: Baseline up to Day 5

  6. Period 1: Change from Baseline in 24-hour UCa in Toilet Trained Participants

    Time frame: Baseline up to Day 5

  7. Period 1: Change from Baseline in Spot Ratio of UCa/Urinary Creatinine (UCr) In Non-toilet Trained Participants

    Time frame: Baseline up to Day 5

  8. Period 3: Number of Participants with Blood iPTH Within the Reference Range

    Time frame: Week 25 (post-dose)

  9. Period 3: Number of Participants with Blood Phosphate Within the Reference Range

    Time frame: Week 25

  10. Period 3: Number of Participants with Blood Magnesium Within the Reference Range

    Time frame: Week 25

  11. Period 3: Number of Participants with Blood 1,25-(OH)2 Vitamin D Within the Reference Range

    Time frame: Week 25

  12. Periods 1, 2, and 3: Change from Baseline in Short Form-10 Health Survey for Children (SF-10) in Participants Aged ≥6 Years

    Time frame: Baseline up to Week 25

  13. Periods 1, 2, and 3: Dose of Calcium Supplements and/or Active Vitamin D Analogs Used as Rescue Therapy

    Time frame: 25 weeks

  14. Periods 1, 2, and 3: Dosing Frequency of Calcium Supplements and/or Active Vitamin D Analogs Used as Rescue Therapy

    Time frame: 25 weeks

  15. Periods 1, 2, 3, and LTE: Number of Participants with Adverse Events (AEs) and Serious AEs (SAEs)

    Time frame: 145 weeks

  16. LTE: Change from Baseline in Blood cCa

    Time frame: Baseline up to 145 weeks

  17. LTE: Change from Baseline in Blood iPTH Concentration

    Time frame: Baseline up to 145 weeks

  18. LTE: Change from Baseline in Blood Phosphate Concentration

    Time frame: Baseline up to 145 weeks

  19. LTE: Change from Baseline in Blood 1,25-(OH)2 Vitamin D Concentration

    Time frame: Baseline up to 145 weeks

  20. LTE: Change from Baseline in Blood Magnesium Concentration

    Time frame: Baseline up to 145 weeks

  21. LTE: Change from Baseline in 24-hour UCa In Toilet Trained Participants

    Time frame: Baseline up to 145 weeks

  22. LTE: Change from Baseline in Spot Ratio of UCa/UCr In Non-toilet Trained Participants

    Time frame: Baseline up to 145 weeks

  23. LTE: Change from Baseline in SF-10 in Participants Aged ≥6 Years

    Time frame: Baseline up to 145 weeks

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2025
First posted
Jul 23, 2025
StartActual
Jan 30, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2030
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07080385
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Jan 30, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Apr 22, 2026

Study contacts

Medical Information
Contact
MedInfo@bridgebio.com
650-600-3610
Calcilytix Medical Director
study director · Calcilytix Therapeutics, Inc., a BridgeBio company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Encaleret

Start the discussion